Plasma ACE2 species are differentially altered in COVID-19 patients
© 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology..
Studies are needed to identify useful biomarkers to assess the severity and prognosis of COVID-19 disease, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus. Here, we examine the levels of various plasma species of the SARS-CoV-2 host receptor, the angiotensin-converting enzyme 2 (ACE2), in patients at different phases of the infection. Human plasma ACE2 species were characterized by immunoprecipitation and western blotting employing antibodies against the ectodomain and the C-terminal domain, using a recombinant human ACE2 protein as control. In addition, changes in the cleaved and full-length ACE2 species were also examined in serum samples derived from humanized K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2. ACE2 immunoreactivity was present in human plasma as several molecular mass species that probably comprise truncated (70 and 75 kDa) and full-length forms (95, 100, 130, and 170 kDa). COVID-19 patients in the acute phase of infection (n = 46) had significantly decreased levels of ACE2 full-length species, while a truncated 70-kDa form was marginally higher compared with non-disease controls (n = 26). Levels of ACE2 full-length species were in the normal range in patients after a recovery period with an interval of 58-70 days (n = 29), while the 70-kDa species decreased. Levels of the truncated ACE2 species served to discriminate between individuals infected by SARS-CoV-2 and those infected with influenza A virus (n = 17). In conclusion, specific plasma ACE2 species are altered in patients with COVID-19 and these changes normalize during the recovery phase. Alterations in ACE2 species following SARS-CoV-2 infection warrant further investigation regarding their potential usefulness as biomarkers for the disease process and to asses efficacy during vaccination.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 35(2021), 8 vom: 16. Aug., Seite e21745 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
García-Ayllón, María-Salud [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACE2 |
|---|
| Anmerkungen: |
Date Completed 08.07.2021 Date Revised 16.09.2021 published: Print ErratumIn: FASEB J. 2021 Sep;35(9):e21857. - PMID 34403542 Citation Status MEDLINE |
|---|
| doi: |
10.1096/fj.202100051R |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327381957 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327381957 | ||
| 003 | DE-627 | ||
| 005 | 20231225200649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1096/fj.202100051R |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327381957 | ||
| 035 | |a (NLM)34191346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a García-Ayllón, María-Salud |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma ACE2 species are differentially altered in COVID-19 patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2021 | ||
| 500 | |a Date Revised 16.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: FASEB J. 2021 Sep;35(9):e21857. - PMID 34403542 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology. | ||
| 520 | |a Studies are needed to identify useful biomarkers to assess the severity and prognosis of COVID-19 disease, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus. Here, we examine the levels of various plasma species of the SARS-CoV-2 host receptor, the angiotensin-converting enzyme 2 (ACE2), in patients at different phases of the infection. Human plasma ACE2 species were characterized by immunoprecipitation and western blotting employing antibodies against the ectodomain and the C-terminal domain, using a recombinant human ACE2 protein as control. In addition, changes in the cleaved and full-length ACE2 species were also examined in serum samples derived from humanized K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2. ACE2 immunoreactivity was present in human plasma as several molecular mass species that probably comprise truncated (70 and 75 kDa) and full-length forms (95, 100, 130, and 170 kDa). COVID-19 patients in the acute phase of infection (n = 46) had significantly decreased levels of ACE2 full-length species, while a truncated 70-kDa form was marginally higher compared with non-disease controls (n = 26). Levels of ACE2 full-length species were in the normal range in patients after a recovery period with an interval of 58-70 days (n = 29), while the 70-kDa species decreased. Levels of the truncated ACE2 species served to discriminate between individuals infected by SARS-CoV-2 and those infected with influenza A virus (n = 17). In conclusion, specific plasma ACE2 species are altered in patients with COVID-19 and these changes normalize during the recovery phase. Alterations in ACE2 species following SARS-CoV-2 infection warrant further investigation regarding their potential usefulness as biomarkers for the disease process and to asses efficacy during vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a plasma | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Moreno-Pérez, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a García-Arriaza, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Rincón, José-Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés-Gómez, María-Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Brinkmalm, Gunnar |e verfasserin |4 aut | |
| 700 | 1 | |a Andrés, Mariano |e verfasserin |4 aut | |
| 700 | 1 | |a León-Ramírez, José-Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Boix, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Gil, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Mariano |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Sáez-Valero, Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t FASEB journal : official publication of the Federation of American Societies for Experimental Biology |d 1989 |g 35(2021), 8 vom: 16. Aug., Seite e21745 |w (DE-627)NLM01261730X |x 1530-6860 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:8 |g day:16 |g month:08 |g pages:e21745 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1096/fj.202100051R |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 8 |b 16 |c 08 |h e21745 | ||